Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Date:11/7/2013

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 7, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced third quarter 2013 financial results and will address frequently asked questions from investors during the quarterly conference call.  Questions, including recent inquiries regarding the clinical development program and prostate cancer market landscape, were submitted via the Company's website and other communication channels.  

The Company will discuss timelines for the primary registration Phase 3 SYNERGY trial, designed to evaluate a survival benefit for custirsen in combination with first-line docetaxel chemotherapy in men with metastatic castrate-resistant prostate cancer (CRPC). 

The planned efficacy interim analysis for SYNERGY has not yet occurred.  Once the interim analysis has been conducted and the Independent Data Monitoring Committee (IDMC) has rendered their recommendation, an update will be provided.  Final SYNERGY results continue to be expected by mid-2014; however, results could be announced sooner in the event the IDMC recommends an early unblinding of the trial.

"We are pleased with the tremendous clinical development progress of both custirsen and apatorsen in 2013,  and are excited about the future as we approach key data announcements for both of these product candidates," stated Scott Cormack, President and CEO of OncoGenex.  "We continue to execute according to plan and remain confident in our ability to change the lives of people living with cancer."

Third Quarter 2013 Financial Update and Results

  • Revenue for the three and nine months ended September 30, 2013 increased to $9.9 million and $21.3 million, respectively.  This compares to $6.6 million and $10.3
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
    3. OncoGenex to Present at Credit Suisse Healthcare Investor Conference
    4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    6. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
    7. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    8. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    9. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    10. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    11. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... 30, 2014  AtheroNova Inc. (OTCBB: AHRO), a ... of compounds to safely regress atherosclerotic plaque and ... its partner, CardioNova, has accomplished first dosing of ... AtheroNova,s lead compound, AHRO-001.  This Phase 1b trial ... 1 safety trial completed in February 2014, in ...
    (Date:7/30/2014)... Hartford, CT (PRWEB) July 30, 2014 ... economic development organization based in East Hartford, Conn., was ... on Phase II of a project that will determine ... facility in rural north-central Connecticut. USDA Rural Development provided ... (RBEG) program for the second phase of the feasibility ...
    (Date:7/30/2014)... 2014 Immunology Summit-2014 ... Principle Investigators, scientists in the field, which includes ... at Case Western Reserve University School of Medicine, ... on “The effects of recombinant human IL-6 ... metalloproteinase-9”. Arya Biragyn, a Senior investigator at National ...
    (Date:7/29/2014)... 2014 “PharmaSphere: Emerging Biotech Investment ... Capital Funding” report provides in-depth analysis of the ... and venture capital segments of the financial industry, ... have significant impact on the future of emerging ... the report identifies regions of the world that ...
    Breaking Biology Technology:AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4
    ... KALAMAZOO, Mich., Oct. 28 Stryker Corporation (NYSE: SYK ... District of Massachusetts has returned an indictment charging Stryker Biotech ... with wire fraud, conspiracy to defraud the U.S. Food and ... statements to the FDA. The Company disclosed in March of ...
    ... INCLINE VILLAGE, Nev., Oct. 28 PDL BioPharma, Inc. ... has priced a $300 million securitization transaction intended to ... , Upon closing of the transaction, which is expected ... sell to QHP Royalty Sub LLC ("QHP"), a newly-formed ...
    ... , GAITHERSBURG, Md., Oct. 28 GenVec, Inc. (Nasdaq: ... the third quarter ended September 30, 2009 on Thursday, November ... call at 10:00 a.m. EST on Friday, November 6, 2009 ... http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ) , To listen to ...
    Cached Biology Technology:Stryker Statement in Response to the Indictment of Its Biotech Division 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 3GenVec Announces Third Quarter 2009 Results Conference Call 2
    (Date:7/30/2014)... pledge of $1 million from the Cornelia Cogswell Rossi ... Biometry Center. , The newly established Connie ... to develop a greater breadth and depth of knowledge ... the pace of research to improve human health. , ... for the Laboratory and its external partners, supporting research ...
    (Date:7/30/2014)... July 30, 2014 ResearchMoz ... Government Biometric Systems Market 2014-2024   Business Strategies, Industry ... Biometric Systems Market 2014-2024" offers the reader detailed ... the next ten years, alongside potential market opportunities ... forecasts. To view the table of ...
    (Date:7/30/2014)... across-the-board increase in Impact Factors for its molecular ... Reports (Thomson Reuters, 2014) show that Clinical ... in Biochemistry , Biochemical Society Transactions ... in their Impact Factors. The journals are owned ... Press Limited. , 2014 Impact Factors (2013 Impact ...
    Breaking Biology News(10 mins):Rossi Foundation pledges $1M for JAX neurobehavioral research center 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10Across-the-board Impact Factor increases for Portland Press Limited 2
    ... / b3c newswire / - Kinaxo Biotechnologies GmbH has ... identify the protein kinase mTOR as a new ... a non-steroidal, anti-inflammatory Cox-2 inhibitor approved for the ... In addition, celecoxib’s anti-proliferative effect has earned it ...
    ... of memories for a lifetime. But when our eyes ... also creates temporary memories that help us process complex ... For decades, scientists have held that such short-term memories ... the course of several seconds. Now researchers at ...
    ... of healthy people can cause serious infections in premature ... university Karolinska Institutet have now found an explanation for ... to the skin and quickly develop dynamic ecosystems: the ... establishes itself on the child,s skin and mucous ...
    Cached Biology News:KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex 2Some short-term memories die suddenly, no fading 2Tufted bacteria cause infection in premature babies 2
    Recombinant Feline IL-2, CF...
    Recombinant Equine IL-4, CF...
    Recombinant Rat Leptin, CF...
    VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
    Biology Products: